The New Era of EU Clinical Trials

The European clinical trial landscape has completed its most significant regulatory transition in decades. By January 31, 2025, the transition period for the European Union's Clinical Trials Regulation (CTR, Regulation (EU) No 536/2014) ended, making the Clinical Trials Information System (CTIS) the mandatory single entry point for all clinical trial submissions, substantial modifications, and safety reporting across the EU and EEA.

While the CTR was designed to harmonise and simplify trial management across member states, it has coincided with a rapid operational shift toward decentralised clinical trials (DCTs) and remote monitoring. For Clinical Operations Directors, navigating this dual transition of a centralised submission portal and decentralised trial execution requires a fundamental restructuring of operational workflows, data privacy protocols, and site monitoring strategies.

Remote Monitoring and the rSDV Challenge

During the pandemic, regulators granted temporary concessions to allow Remote Source Data Verification (rSDV) to maintain trial continuity. Today, rSDV has transitioned from an emergency measure into a standard component of risk-based monitoring strategies.

However, implementing rSDV across multiple European jurisdictions introduces significant regulatory and operational friction:

• The GDPR Compliance Hurdle: Under the General Data Protection Regulation (GDPR), patient medical records contain highly sensitive health data. Accessing these records remotely requires strict technical and organisational safeguards, including multi-factor authentication, end-to-end encryption, and secure view-only access.

• Joint Controller Liability: The Principal Investigator (PI), the clinical site institution, and the sponsor are increasingly designated as joint data controllers under GDPR. This requires detailed, legally binding data-sharing agreements that define specific liabilities for data breaches during remote monitoring sessions.

• National Variations: Although the CTR harmonises the clinical trial application process via CTIS, national competent authorities and ethics committees retain sovereign control over data privacy laws and hospital IT security policies. A remote monitoring protocol that is approved in Germany may face local IT or legal restrictions when deployed in France or Poland.

Implications for Clinical Operations Directors

To successfully execute clinical trials in this harmonised yet operationally fragmented environment, Clinical Operations Directors must adapt their quality management systems in three key areas:

• CTIS Dossier Integration: Monitoring plans, including the justification and technical setup for rSDV, must be clearly documented within the clinical trial application dossier submitted via CTIS, ensuring early alignment with all Member States Concerned (MSCs).

• Risk-Based Quality Management: Developing Standard Operating Procedures (SOPs) that justify the use of remote monitoring based on the trial's specific risk profile, minimizing patient burden while maintaining absolute data integrity.

• Site IT Integration: Collaborating with clinical research organisations (CROs) and hospital IT departments to establish validated, GDPR-compliant remote access portals, reducing the administrative burden on investigator site staff.

Sourcing Harmonisation-Ready Clinical Ops Leaders

As pharma services and CROs adapt to these new EU standards, the demand for Clinical Operations Directors with hands-on CTIS and DCT experience has surged.

RSA prioritises several core competencies when placing operational leaders in the European clinical trials sector:

• CTIS Submission Fluency: A proven track record of navigating the CTIS portal, managing multi-country submissions, and resolving requests for information (RFIs) within the strict regulatory timelines of the CTR.

• Decentralised Trial Design: Experience implementing remote monitoring, home-nursing protocols, and direct-to-patient (DtP) IP shipment logistics.

• GDPR and Data Privacy Expertise: A deep understanding of data protection frameworks in clinical research, with experience structuring joint controller agreements and managing national privacy requirements across multiple EU member states concerned.

By placing strategically minded, operationally fluent leaders at the helm of clinical trials, sponsors and CROs can successfully navigate the complexities of the CTIS portal, mitigate data privacy risks, and accelerate clinical development timelines across the European Union.